Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.

Item

http://www.wikidata.org/entity/Q36599597

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.

@ast

Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.

@en

type

Item

label

Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.

@ast

Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.

@en

prefLabel

Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.

@ast

Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.

@en

P1476

Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.

@en

P2093

Angela Colbers

http://www.w3.org/2001/XMLSchema#string

Carlijn Litjens

http://www.w3.org/2001/XMLSchema#string

David Burger

http://www.w3.org/2001/XMLSchema#string

P2860

The Simcyp population-based ADME simulator

Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability.

Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1.

Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers.

Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data.

Investigating the contribution of CYP2J2 to ritonavir metabolism in vitro and in vivo.

Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily.

Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients.

Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir

Atazanavir pharmacokinetics with and without tenofovir during pregnancy

P2888

s40262-015-0325-8

P304

381-396

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40262-015-0325-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Rick Greupink

Frans G Russel

P577

2015-09-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

282037004

http://www.w3.org/2001/XMLSchema#string

P698

26369773

http://www.w3.org/2001/XMLSchema#string

P932

4761019

http://www.w3.org/2001/XMLSchema#string